Brief: Polyphor Closes Phase III PRISM Studies Of Murepavadin Intravenous Formulation
17/07/2019 06:10
July 17 (Reuters) - Polyphor AG POLN.S :
* EQS-ADHOC: POLYPHOR CLOSES THE PHASE III PRISM STUDIES OF MUREPAVADIN INTRAVENOUS
FORMULATION
AND EVALUATES FURTHER PRODUCT IMPROVEMENT OPTIONS
* DEVELOPMENT OF POLYPHOR'S IMMUNO-ONCOLOGY CANDIDATE, BALIXAFORTIDE (POL6326) CONTINUES AS
PLANNED WITH FULL COMMITMENT
Source text for Eikon: ID:nEQblTbZSa
Further company coverage: POLN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Spexis AG
See all newsBrief: Spexis AG: Expects Audit Of 2023 Financials Will Not Be Completed By 31 July 2024
Brief: Spexis Launches Appeal Against Six Exchange Regulation Decision To Suspend Trading Of Its Shares.
Brief: Spexis AG- Audit Costs Have Not Been Approved Yet And Further Extension May Be Required
Brief: Spexis Announces CFO Hernan Levett Has Decided To Pursue New Career Outside Company
Brief: Spexis: Total Loss Of CHF 3.9 Mln In H1 2023